Dr. Khan and Dr. Keefe present a multidisciplinary, image-guided approach to spinal and extraspinal tumor management, focusing on ablative techniques plus cement augmentation as a complement (not replacement) to surgery and radiotherapy.
Epidemiology and imaging
-
Metastatic spine disease is very common in stage‑4 cancer, but only a subset develops neurologic compromise or severe pain that warrants intervention; the spine is highlighted as the third most common metastatic site after lung and liver.
-
Conventional anatomical MRI/CT is often insufficient to distinguish radiation necrosis, benign lesions, and recurrent tumor, so the speakers emphasize selected use of advanced imaging (diffusion, perfusion) both for diagnosis and biopsy targeting.
Decision frameworks and tumor board
-
Patients are discussed in a dedicated spine tumor board including surgery, radiation oncology, interventional radiology/neurointervention, medical oncology, and palliative care to sequence therapies and define fallback plans (Plan B/C).
-
The Bilsky ESCC grading and SINS are considered mandatory elements of radiology reporting; SINS 0–6 goes to radiation, 13–18 to surgery, and the “gray zone” 7–12 is where interventional procedures (ablation + augmentation) are positioned.
RFA + vertebral augmentation (kypho/vertebroplasty)
-
Dr. Keefe outlines percutaneous access to the pathologic vertebral body, radiofrequency ablation of the tumor, optional balloon kyphoplasty for height restoration, then PMMA cement injection to stabilize and control pain.
-
NCCN and metastatic spine disease algorithms place RFA + augmentation in multiple scenarios: painful metastases with or without fracture, progression after prior RT/surgery, and stable/unstable pathologic compression fractures, but not for epidural disease near the canal.
Mechanisms, outcomes, and technical limits
-
RFA uses high‑frequency alternating current to generate heat (target ~70 °C) causing coagulation necrosis; temperatures <70 °C risk undertreatment, >90 °C risk charring and impedance rise.
-
Clinical series show faster pain relief with RFA ± cement (often within days) versus external beam radiation alone (up to ~6 weeks), and combination therapy yields higher complete pain response rates than RT alone.
-
Cement stabilization relieves pain by eliminating cortical micromotion at the fracture site, analogous to splinting a long bone but achieved internally rather than with external bracing.
Indications, levels, and complications
-
Typical practice is to treat up to about 4–5 vertebral levels per session, constrained by PMMA load, reimbursement, and the concept of oligometastatic vs diffuse disease; more widespread disease is not considered an ablation problem.
-
Key risks include cement leakage (posteriorly or into venous structures) and edema‑related cord compromise; preservation of the PLL is stressed, and peri‑procedural steroids are used when epidural disease is close by.
Case illustrations
-
Multiple cases demonstrate dramatic pain reduction (often from 9–10/10 to 0–1/10 within weeks) after RFA + kypho in gastric, spindle‑cell, and breast cancer with thoracic, lumbar, and sacral involvement, including complex reconstructions at T1 and sacral ala/S1–S2.
-
Technical pearls include use of hybrid CT–fluoro guidance, intra‑procedural CT to assess cement fill, and route selection (e.g., longitudinal S1 canal access starting below the thecal sac) in sacral disease.
Other ablation modalities: cryo and microwave
-
Cryoablation is presented as particularly useful for sclerotic lesions and paraspinal/soft‑tissue masses because the ice ball is directly visible, allowing precise contouring around critical structures; its drawbacks are longer freeze–thaw cycles and procedure time.
-
Microwave ablation offers rapid heating, larger and more predictable ablation zones, less sensitivity to heat‑sink effects, and better performance in sclerotic bone compared with RFA, making it attractive for pelvic and mixed‑density vertebral metastases.
Extended indications and experimental techniques
-
The team reports use of ablation in selected primary tumors (e.g., osteoblastoma, giant cell tumor) typically as a salvage or surgery‑sparing option, not first‑line for malignant primaries such as chordoma.
-
One illustrative acetabular giant cell tumor case uses staged ablation plus PMMA mixed with zoledronic acid (Zometa) over several sessions, effectively “re‑creating” an acetabulum and avoiding major reconstructive surgery in a young military patient.